Skip to main content

Advertisement

Log in

Improving medication adherence among community-dwelling seniors with cognitive impairment: a systematic review of interventions

  • Review Article
  • Published:
International Journal of Clinical Pharmacy Aims and scope Submit manuscript

Abstract

Background Medication non-adherence may lead to poor therapeutic outcomes. Cognitive functions deteriorate with age, contributing to decreased adherence. Interventions have been tested to improve adherence in seniors with cognitive impairment or Alzheimer disease (AD), but high-quality systematic reviews are lacking. It remains unclear which interventions are promising. Objectives We conducted a systematic review to identify, describe, and evaluate interventions aimed at improving medication adherence among seniors with any type of cognitive impairment. Methods Following NICE guidance, databases and websites were searched using combinations of controlled and free vocabulary. All adherence-enhancing interventions and study designs were considered. Studies had to include community dwelling seniors, aged 65 years or older, with cognitive impairment, receiving at least one medication for a chronic condition, and an adherence measure. Study characteristics and methodological quality were assessed. Results We identified 13 interventions, including six RCTs. Two studies were of poor, nine of low/medium and two of high quality. Seven studies had sample sizes below 50 and six interventions focused on adherence to AD medication. Six interventions tested a behavioral, four a medication oriented, two an educational and one a multi-faceted approach. Studies rarely assessed therapeutic outcomes. All but one intervention showed improved adherence. Conclusion Three medium quality studies showed better adherence with patches than with pills for AD treatment. Promising interventions used educational or reminding strategies, including one high quality RCT. Nine studies were of low/moderate quality. High quality RCTs using a theoretical framework for intervention selection are needed to identify strategies for improved adherence in these seniors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Adapted from Moher et al. [36]

Similar content being viewed by others

References

  1. Ramage-Morin PL. Medication use among senior Canadians. Health Rep. 2009;20:37–44.

    PubMed  Google Scholar 

  2. Canadian Institute for Health Information. Drug use among seniors on public drug programs in Canada, 2012. Ottawa, ON. May 2014.

  3. National Center for Health Statistics. Health, United States, 2014: In Brief. Hyattsville, MD2014. DHHS Publication No. 2015–1210.

  4. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487–97.

    Article  CAS  PubMed  Google Scholar 

  5. Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppart T, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73:691–705.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Kröger E, van Marum R, Souverein P, Egberts T. Discontinuation of cholinesterase inhibitor treatment and determinants thereof in the Netherlands: a retrospective cohort study. Drugs Aging. 2010;27:663–75.

    Article  PubMed  Google Scholar 

  7. Sabaté E. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization; 2003.

    Google Scholar 

  8. Perreault S, Ellia L, Dragomir A, Cote R, Blais L, Berard A, et al. Effect of statin adherence on cerebrovascular disease in primary prevention. Am J Med. 2009;122:647–55.

    Article  CAS  PubMed  Google Scholar 

  9. Perreault S, Yu AY, Cote R, Dragomir A, White-Guay B, Dumas S. Adherence to antihypertensive agents after ischemic stroke and risk of cardiovascular outcomes. Neurology. 2012;79:2037–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Ross S, Samuels E, Gairy K, Iqbal S, Badamgarav E, Siris E. A meta-analysis of osteoporotic fracture risk with medication nonadherence. Value Health. 2011;14:571–81.

    Article  PubMed  Google Scholar 

  11. Imaz I, Zegarra P, Gonzalez-Enriquez J, Rubio B, Alcazar R, Amate JM. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int. 2010;21:1943–51.

    Article  CAS  PubMed  Google Scholar 

  12. Arlt S, Lindner R, Rosler A, von Renteln-Kruse W. Adherence to medication in patients with dementia: predictors and strategies for improvement. Drugs Aging. 2008;25:1033–47.

    Article  PubMed  Google Scholar 

  13. Petersen RC, Caracciolo B, Brayne C, Gauthier S, Jelic V, Fratiglioni L. Mild cognitive impairment: a concept in evolution. J Intern Med. 2014;275:214–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Tuokko H, Morris C, Ebert P. Mild cognitive impairment and everyday functioning in older adults. Neurocase. 2005;11:40–7.

    Article  PubMed  Google Scholar 

  15. Panza F, D’Introno A, Colacicco AM, Capurso C, Del Parigi A, Caselli RJ. Current epidemiology of mild cognitive impairment and other predementia syndromes. Am J Geriatr Psychiatry. 2005;13:633–44.

    Article  PubMed  Google Scholar 

  16. Graham JE, Rockwood K, Beattie BL, Eastwood R, Gauthier S, Tuokko H, et al. Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet. 1997;349:1793–6.

    Article  CAS  PubMed  Google Scholar 

  17. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183–94.

    Article  CAS  PubMed  Google Scholar 

  18. Ward A, Arrighi HM, Michels S, Cedarbaum JM. Mild cognitive impairment: disparity of incidence and prevalence estimates. Alzheimers Dement J Alzheimers Assoc. 2012;8:14–21.

    Article  Google Scholar 

  19. Langa KM, Levine DA. The diagnosis and management of mild cognitive impairment: a clinical review. JAMA. 2014;312:2551–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Bickel H, Mosch E, Seigerschmidt E, Siemen M, Forstl H. Prevalence and persistence of mild cognitive impairment among elderly patients in general hospitals. Dement Geriatr Cogn Disord. 2006;21:242–50.

    Article  CAS  PubMed  Google Scholar 

  21. Mitchell AJ, Shiri-Feshki M. Rate of progression of mild cognitive impairment to dementia—meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand. 2009;119:252–65.

    Article  CAS  PubMed  Google Scholar 

  22. Alzheimer’s Disease International, Prince M, Wimo A, Guerchet M, Ali GC, Wu YT, Prina M. World Alzheimer Report 2015. The Global Impact of Dementia. An analysis of prevalence, incidence, cost and trends. London, UK, August 2015.

  23. Okuno J, Yanagi H, Tomura S. Is cognitive impairment a risk factor for poor compliance among Japanese elderly in the community? Eur J Clin Pharmacol. 2001;57:589–94.

    Article  CAS  PubMed  Google Scholar 

  24. Hughes CM. Medication non-adherence in the elderly: how big is the problem? Drugs Aging. 2004;21:793–811.

    Article  PubMed  Google Scholar 

  25. Luzny J, Ivanova K, Jurickova L. Non-adherence in seniors with dementia—a serious problem of routine clinical practice. Acta Med (Hradec Kralove). 2014;57:73–7.

    Article  Google Scholar 

  26. Nieuwlaat R, Wilczynski N, Navarro T, Hobson N, Jeffery R, Keepanasseril A, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2014;11:CD000011.

    Google Scholar 

  27. Van Eijken M, Tsang S, Wensing M, De Smet PAGM, Grol RPTM. Interventions to improve medication compliance in older patients living in the community: a systematic review of the literature. Drugs Aging. 2003;20:229–40.

    Article  PubMed  Google Scholar 

  28. Schlenk EA, Dunbar-Jacob J, Engberg S. Medication non-adherence among older adults: a review of strategies and interventions for improvement. J Gerontol Nurs. 2004;30:33–43.

    Article  PubMed  Google Scholar 

  29. George J, Elliott RA, Stewart DC. A systematic review of interventions to improve medication taking in elderly patients prescribed multiple medications. Drugs Aging. 2008;25:307–24.

    Article  PubMed  Google Scholar 

  30. Banning M. A review of interventions used to improve adherence to medication in older people. Int J Nurs Stud. 2009;46:1505–15.

    Article  PubMed  Google Scholar 

  31. Conn VS, Hafdahl AR, Cooper PS, Ruppar TM, Mehr DR, Russell CL. Interventions to improve medication adherence among older adults: meta-analysis of adherence outcomes among randomized controlled trials. Gerontologist. 2009;49:447–62.

    Article  PubMed  Google Scholar 

  32. Campbell NL, Boustani MA, Skopelja EN, Gao S, Unverzagt FW, Murray MD. Medication adherence in older adults with cognitive impairment: a systematic evidence-based review. Am J Geriatr Pharmacother. 2012;10:165–77.

    Article  PubMed  Google Scholar 

  33. Maxwell CJ, Stock K, Seitz D, Herrmann N. Persistence and adherence with dementia pharmacotherapy: relevance of patient, provider, and system factors. Can J Psychiatry. 2014;59:624–31.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011. Available from www.handbook.cochrane.org.

  35. National Institute for Health and Care Excellence. Methods for the development of NICE public health guidance. 3rd ed. London: National Institute for Health and Care Excellence; 2012. https://www.nice.org.uk/process/pmg4/chapter/appendix-f-quality-appraisal-checklist-quantitative-intervention-studies.

  36. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Stewart LA. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.

  37. Hwang W, Weller W, Ireys H, Anderson G. Out-of-pocket medical spending for care of chronic conditions. Health Aff (Millwood). 2001;20:267–78.

    Article  CAS  Google Scholar 

  38. van Dulmen S, Sluijs E, van Dijk L, de Ridder D, Heerdink R, Bensing J. Patient adherence to medical treatment: a review of reviews. BMC Health Serv Res. 2007;7:55.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Hawkins LA, Firek CJ. Testing a novel pictorial medication sheet to improve adherence in veterans with heart failure and cognitive impairment. Heart Lung J Crit Care. 2014;43:486–93.

    Article  Google Scholar 

  40. Insel KC, Cole L. Individualizing memory strategies to improve medication adherence. Appl Nurs Res. 2005;18:199–204.

    Article  PubMed  Google Scholar 

  41. Kripalani S, Schmotzer B, Jacobson TA. Improving medication adherence through graphically enhanced interventions in coronary heart disease (IMAGE-CHD): a randomized controlled trial. J Gen Intern Med. 2012;27:1609–17.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA. 2006;296:2563–71.

    Article  CAS  PubMed  Google Scholar 

  43. Leirer VO, Morrow DG, Tanke ED, Pariante GM. Elders’ nonadherence: its assessment and medication reminding by voice mail. Gerontologist. 1991;31:514–20.

    Article  CAS  PubMed  Google Scholar 

  44. Ownby RL, Hertzog C, Czaja SJ. Tailored information and automated reminding to improve medication adherence in Spanish- and English-speaking elders treated for memory impairment. Clin Gerontol. 2012;35:221–38.

    Article  Google Scholar 

  45. Smith GE, Lunde AM, Hathaway JC, Vickers KS. Telehealth home monitoring of solitary persons with mild dementia. Am J Alzheimer’s Dis Other Dement. 2007;22:20–6.

    Article  Google Scholar 

  46. Tian H, Abouzaid S, Chen W, Kahler KH, Kim E. Patient adherence to transdermal rivastigmine after switching from oral donepezil: a retrospective claims database study. Alzheimer Dis Assoc Disord. 2013;27:182–6.

    Article  CAS  PubMed  Google Scholar 

  47. Adler G, Mueller B, Articus K. The transdermal formulation of rivastigmine improves caregiver burden and treatment adherence of patients with Alzheimer’s disease under daily practice conditions. Int J Clin Pract. 2014;68:465–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Oswald WD, Gunzelmann T, Wannenmacher W. Die Compliance von Patienten höheren Lebensalters mit Hirnleistungsstörungen bei Encephabol forte und Encephabol 600 [Compliance of patients with dementia syndrome treated with Encephabol forte and Encephabol 600]. Z Gerontopsychologie Psychiatr. 1993;6:17–25.

    Google Scholar 

  49. Molinuevo JL, Arranz FJ. Impact of transdermal drug delivery on treatment adherence in patients with Alzheimer’s disease. Expert Rev Neurother. 2012;12:31–7.

    Article  CAS  PubMed  Google Scholar 

  50. Kamimura T, Ishiwata R, Inoue T. Medication reminder device for the elderly patients with mild cognitive impairment. Am J Alzheimer’s Dis Other Dement. 2012;27:238–42.

    Article  Google Scholar 

  51. Watanabe N, Yamamura K, Suzuki Y, Umegaki H, Shigeno K, Matsushita R, et al. Pharmacist-based donepezil outpatient consultation service to improve medication persistence. Patient Prefer Adherence. 2012;6:605–11.

    PubMed  PubMed Central  Google Scholar 

  52. Morris JC. The clinical dementia rating (CDR): current version and scoring rules. Neurology. 1993;43:2412–4.

    Article  CAS  PubMed  Google Scholar 

  53. Folstein MF, Folstein SE, McHugh PR. ”Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–98.

    Article  CAS  PubMed  Google Scholar 

  54. Tariq SH, Tumosa N, Chibnall JT, Perry MH 3rd, Morley JE. Comparison of the Saint Louis University mental status examination and the mini-mental state examination for detecting dementia and mild neurocognitive disorder—a pilot study. Am J Geriatr Psychiatry. 2006;14:900–10.

    Article  PubMed  Google Scholar 

  55. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer’s disease. Am J Psychiatry. 1984;141:1356–64.

    Article  CAS  PubMed  Google Scholar 

  56. Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev. 2006; CD005593.

  57. Kröger E, Mouls M, Wilchesky M, Berkers M, Carmichael PH, van Marum R, et al. Adverse drug reactions reported with cholinesterase inhibitors: an analysis of 16 years of individual case safety reports from VigiBase. Ann Pharmacother. 2015;31:1197–206.

    Article  Google Scholar 

  58. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24:67–74.

    Article  CAS  PubMed  Google Scholar 

  59. Khan KS, Dinnes J, Kleijnen J. Systematic reviews to evaluate diagnostic tests. Eur J Obstet Gynecol Reprod Biol. 2001;95:6–11.

    Article  CAS  PubMed  Google Scholar 

  60. Popay J, Roberts H, Sowden A, Petticrew M, Arai Y, Rodgers M, et al. Guidance on the conduct of narrative synthesis in systematic reviews. 1st ed. Lancaster: Institute for Health Research, Bowland Tower East Wing, Lancaster University; 2006.

    Google Scholar 

  61. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008;16:CD000011.

    Google Scholar 

  62. Reeve E, Wiese MD. Benefits of deprescribing on patients’ adherence to medications. Int J Clin Pharm. 2014;36:26–9.

    Article  PubMed  Google Scholar 

  63. Scott IA, Anderson K, Freeman CR, Stowasser DA. First do no harm: a real need to deprescribe in older patients. Med J Aust. 2014;201:390–2.

    Article  PubMed  Google Scholar 

  64. Reeve E, Turner JP. Patients’ perspectives on the brave new word ‘deprescribing’. Int J Pharm Pract. 2015;23:90–1.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors wish to thank the research professionals who worked on this review, Ms Martine Marcotte and Ms Laura Finken, as well as a resident in geriatric medicine who participated in the article selection, Dr Pierre Molin. They also wish to thank Dr. André Tourigny from the CEVQ who was instrumental in initiating this research, and Ms Zorica Djordjevic, librarian at the Hôpital St-Sacrement du CHU de Québec, who contributed to the database search strategy.

Funding

Chair on adherence to treatments, Université Laval (EKröger) and from the Centre d’excellence sur le vieillissement de Québec (CEVQ) and the Réseau québécois de recherche sur le vieillissement du Fonds de recherche du Québec—santé (E Kröger)

Conflicts of interest

None of the authors have any conflict of interest to declare.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Edeltraut Kröger.

Appendix 1

See Table 4.

Table 4 List of websites searched

Appendix 2: PubMed search strategy

  1. 1.

    (“Patient compliance”[Mesh] OR “compliance”[TiAb] OR “compliant”[TiAb] OR “adherence”[TiAb] OR “adherent”[TiAb] OR “persistence”[TiAb] OR “persistent”[TiAb] OR “appropriate use”[TiAb] OR “concordance”[TiAb] OR “patient cooperation”[TiAb] OR “Medication therapy management”[Mesh] OR “drug therapy management”[TiAb] OR “therapy management”[TiAb] OR “treatment management”[TiAb] OR “medication management”[TiAb] OR “self-management”[TiAb] OR “patient education”[TiAb] OR “Treatment refusal”[Mesh] OR “treatment refusal”[TiAb] OR “refusal of treatment”[TiAb] OR “Patient dropouts”[Mesh] OR “Patient dropout*”[TiAb] OR “Treatment dropout*”[TiAb] OR “dropouts”[TiAb] OR “dropout”[TiAb] OR “Prescription Drug Misuse”[Mesh] OR “Self administration”[Mesh])

  2. 2.

    (“Cognition disorders”[Mesh] OR “impaired cognition”[TiAb] OR “impaired function”[TiAb] OR “impaired memory”[TiAb] OR “function impairment”[TiAb] OR “functional impairment”[TiAb] OR “memory impairment”[TiAb] OR “cognitive loss”[TiAb] OR “cognitive dysfunction”[TiAb] OR “cognitive deficit”[TiAb] OR “cognitive decline”[TiAb] OR “cognitive defect”[TiAb] OR “cognitive problems”[TiAb] OR “memory dysfunction”[TiAb] OR “memory loss”[TiAb] OR “memory deficit”[TiAb] OR “memory decline”[TiAb] OR “memory defect”[TiAb] OR “memory problems”[TiAb] OR “cognitive abilities”[TiAb] OR “executive function”[TiAb] OR “cognitively impaired”[TiAb] OR “Cognitive impairment”[TiAb] OR “cognitive disorder”[TiAb] OR “Dementia””[Mesh])

  3. 3.

    #1 AND #2

Filters activated: Humans, English, French, German, Aged: 65+ years.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kröger, E., Tatar, O., Vedel, I. et al. Improving medication adherence among community-dwelling seniors with cognitive impairment: a systematic review of interventions. Int J Clin Pharm 39, 641–656 (2017). https://doi.org/10.1007/s11096-017-0487-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11096-017-0487-6

Keywords

Navigation